Literature DB >> 12111414

Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus.

C A Holland-Staley1, L C Kovari, E M Golenberg, K J Pobursky, D L Mayers.   

Abstract

The N-terminal one-third of the hepatitis C virus nonstructural gene 3 (NS3) codes for a serine protease. To investigate natural genetic diversity of this enzyme a nested PCR reaction was developed to obtain NS3 protease sequence data directly from patient strains. This data was used to determine genetic diversity, phylogenetic and evolutionary rates, and selection of variants by interferon therapy. The potential effect of genetic diversity on enzyme structure using molecular modeling was also attempted. Results show significant variability in clinical HCV strains at both the nucleotide (30.2% for 1a and 25.8% for 1b) and amino acid sequences (11.0% for 1a and 9.9% for 1b). Phylogenic analysis shows two distinct clades with two HCV isolates grouping as a sister clade to 1b. Structural analysis reveals that most mutations lie in the N-terminus of the enzyme. When strains were sorted as to whether or not the patient had received antiviral therapy, no difference was found in the number or locations of mutations in 1a strains. However, 1b strains demonstrated an overall drop in the number of positions that were mutated. This study demonstrates significant differences among natural strains that may pose a problem for structure based drug development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12111414     DOI: 10.1007/s00705-002-0807-5

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  6 in total

Review 1.  Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective.

Authors:  Karina Salvatierra; Sabrina Fareleski; Alicia Forcada; F Xavier López-Labrador
Journal:  World J Virol       Date:  2013-02-12

2.  Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients.

Authors:  Aarthi Chary; Mark A Winters; Shyam Kottilil; Alison A Murphy; Michael A Polis; Mark Holodniy
Journal:  J Infect Dis       Date:  2010-09-15       Impact factor: 5.226

3.  Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus.

Authors:  Mark A Winters; Seth L Welles; Mark Holodniy
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

4.  IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin.

Authors:  Anu Osinusi; Aarthi Chary; Mark A Winters; Susanna Naggie; Henry Masur; Michael A Polis; Shyam Kottilil; Mark Holodniy
Journal:  J Med Virol       Date:  2012-10       Impact factor: 2.327

5.  Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6.

Authors:  Ingrid Imhof; Peter Simmonds
Journal:  J Virol       Date:  2010-02-17       Impact factor: 5.103

6.  Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model.

Authors:  Rhea Sumpter; Chunfu Wang; Eileen Foy; Yueh-Ming Loo; Michael Gale
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.